Commercial availability expected in August as the Company advances the rollout of the highest-dose FDA-approved naloxone hydrochloride nasal spray
U.S. naloxone market totals ~$144 million in annual sales and ~9.8 million units annually, represents significant commercial opportunity for REZENOPY™
COMMACK, NY, July 09, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) ("Scienture"), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today announced that it has completed manufacturing of commercial launch inventory and will begin shipments later this month of REZENOPY™ (naloxone hydrochloride) Nasal Spray 10 mg to U.S. pharmaceutical wholesalers. The Company expects REZENOPY™ to become commercially available for purchase in August.
The Company is working with its wholesale distribution partners in preparation for nationwide commercial availability. The initial shipments represent an important step in Scienture's commercial strategy as it expands its portfolio of differentiated specialty pharmaceutical products.
REZENOPY™ is the highest-dose FDA-approved naloxone hydrochloride nasal spray available in the United States, delivering 10 mg of naloxone hydrochloride in a single-use nasal spray device for the emergency treatment of known or suspected opioid overdose. Built on the proven naloxone molecule and a familiar nasal spray delivery platform, REZENOPY™ is designed to provide an important treatment option for overdoses involving highly potent synthetic opioids.
According to IQVIA data (MAT April 2026), the U.S. naloxone market generated approximately $144 million in annual sales across 9.8 million units, highlighting a substantial commercial opportunity for REZENOPY™. In addition, the Company recently expanded payer access with potential coverage reaching more than 100 million covered lives, further strengthening its commercial positioning ahead of product availability.
"Our readiness for wholesale shipments late this month marks a significant commercial milestone for Scienture as we continue executing on the launch of REZENOPY™," said Shankar Hariharan, Executive Chairman and co-CEO of Scienture. "With product ready to enter the pharmaceutical distribution channel, we are well positioned to make REZENOPY™ broadly available to pharmacies, healthcare providers, first responders, and community organizations in August."